Compositions and methods for macrophage conversion

US10098982B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10098982-B2
Application numberUS-201415036822-A
CountryUS
Kind codeB2
Filing dateNov 20, 2014
Priority dateNov 20, 2013
Publication dateOct 16, 2018
Grant dateOct 16, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention describes methods and compositions of hydrogel microspheres for inducing macrophage conversion by sequentially converting a first population of wound macrophages in a wound to M2A macrophages by exposing the first population of wound macrophages to IL-4 and converting a second population of wound macrophages to M2C macrophages by exposing the second population of wound macrophages to IL-10. One aspect describes a method of inducing macrophage conversion in a wound. Another aspect describes compositions and methods of preparing a hydrogel microsphere for wound healing. Yet another aspect describes methods for treating a chronic wound with hydrogel microspheres.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of inducing macrophage conversion in a wound comprising sequentially inducing conversion of a first population of wound macrophages in the wound to M2A macrophages and then converting a second population of wound macrophages in the wound to M2C macrophages, wherein inducing conversion of the macrophages comprises: applying hydrogel microspheres to the wound, wherein the hydrogel microspheres comprise: an inner core of hydrogel polymers bound to one or more selected from the group consisting of: interleukin-10 (IL-10), dexamethasone, and a dexamethasone analog; and an outer shell of hydrogel polymers bound to interleukin-4 (IL-4); inducing conversion of the first population of wound macrophages in the wound to M2A macrophages by exposure to the IL-4 that is released from the outer shell of the hydrogel microspheres; and then inducing conversion of the second population of wound macrophages to M2C macrophages by exposure to the IL-10, dexamethasone, or the dexamethasone analog that is released from the inner core of the hydrogel microspheres. 2. The method of claim 1 , wherein the inner core of hydrogel polymers is bound to interleukin-10 (IL-10) ; and conversion of the second population of wound macrophages to M2C macrophages is induced by exposure to IL-10 that is released from the inner core of the hydrogel microspheres. 3. The method of claim 1 , wherein: the inner core of hydrogel polymers is bound to dexamethasone or a dexamethasone analog, and conversion of the second population of wound macrophages to M2C macrophages is induced by exposure to the dexamethasone or the dexamethasone analog that is released from the inner core of the hydrogel microspheres. 4. The method of claim 3 , wherein the inner core of hydrogel polymers is bound to dexamethasone. 5. The method of claim 1 , wherein: the IL-10 is released by enzymatic cleavage by an enzyme that is present in the wound and the enzyme comprises a matrix metalloprotease that cleaves the IL-10 from the polymer. 6. The method of claim 1 , wherein the IL-10 is released by degradation of the hydrogel polymer. 7. The method of claim 1 , further comprising wherein when the macrophage conversion in the wound occurs, the wound is treated. 8. The method of claim 1 , wherein the wound is a chronic wound. 9. The method of claim 1 , wherein: the inner core of hydrogel polymers is bound to one or more selected from the group consisting of: interleukin-10 (IL-10) and dexamethasone; and conversion of the second population of wound macrophages to M2C macrophages is induced by exposure to IL-10 or dexamethasone that is released from the inner core of the hydrogel microspheres.

Assignees

Inventors

Classifications

  • Immunomodulating agents, i.e. cytokines, interleukins, interferons · CPC title

  • Alginic acid; Derivatives thereof · CPC title

  • Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines · CPC title

  • IL-10 · CPC title

  • Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10098982B2 cover?
The present invention describes methods and compositions of hydrogel microspheres for inducing macrophage conversion by sequentially converting a first population of wound macrophages in a wound to M2A macrophages by exposing the first population of wound macrophages to IL-4 and converting a second population of wound macrophages to M2C macrophages by exposing the second population of wound mac…
Who is the assignee on this patent?
Univ Drexel
What technology area does this patent fall under?
Primary CPC classification A61L26/0066. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).